【摘要】 目的:观察膦甲酸钠联合重组人干扰素α2b治疗宫颈人乳头瘤病毒(HPV)持续感染的临床疗效。方法:选取宫颈HPV持续感染患者65例,按照随机数字表法分为治疗组(n=35)和对照组(n=30)。两组患者均给予重组人干扰素α2b栓10万IU,qod(睡前),治疗时间为3个月;治疗组患者在此基础上给予膦甲酸钠氯化钠注射液250 m L,ivgtt,qd,治疗时间为14 d。观察两组患者根据HPV病毒载量判定的疗效、HPV转阴率、宫颈炎评分、根据宫颈炎评分改善率判定的疗效及不良反应发生情况。结果:治疗组患者根据HPV病毒载量判定的总有效率(94.29%)明显高于对照组(76.67%),差异有统计学意义(P<0.05);治疗组患者HPV转阴率(77.14%)明显高于对照组(36.67%),差异有统计学意义(P<0.05)。两组患者宫颈炎评分均较治疗前明显降低,且治疗组[(1.49±0.70)分]明显低于对照组[(1.97±0.89)分],差异均有统计学意义(P<0.05);治疗组患者根据宫颈炎评分改善率判定的总有效率(88.57%)明显高于对照组(73.33%),差异有统计学意义(P<0.05)。两组患者治疗过程中均未见不良反应发生。结论:膦甲酸钠联合重组人干扰素α2b能有效抑制HPV病毒复制、提高HPV转阴率、缓解宫颈炎症状,且安全性较高。更多还原

【Abstract】 OBJECTIVE:To observe the clinical efficacy of foscarnet sodium combined with recombinant human interferon α2b in the treatment of persistent infection of cervical HPV. METHODS:A total of 65 patients infected with HPV were enrolled in the study and divided into treatment group(n=35)and control group(n=30). Both groups were treated with recombinant human interferon α2b 100 000 IU,qod(at bedtime),for 3 months;treatment group was additionally treated with Foscarnet chloride and sodium chloride injection 250 m L,ivgtt,qd,for 14 d. Therapeutic efficacy based on HPV viral loading amount,negative rate of HPV and cervicitis score were observed in 2 groups as well as therapeutic efficacy based on cervicitis score improvement rate and the occurrence of ADR. RESULTS:Total effective rate based on HPV viral loading amount of treatment group(94.29%)was significantly higher than that of control group(76.67%),with statistical significance(P<0.05). The negative rate of HPV in treatment group(77.14%)was significantly higher than in control group(36.67%),with statistical significance(P<0.05).The cervicitis scores of 2 groups were decreased significantly compared to before treatment,the treatment group [(1.49±0.70)score] was significantly lower than the control group [(1.97 ± 0.89)score],with statistical significance(P<0.05). The total effective rate based on improvement rate of cervicitis scores of treatment groups(88.57%) was significantly higher than that of control group(73.33%),with statistical significance(P<0.05). No ADR was found in 2 groups during treatment. CONCLUSIONS:Foscarnet sodium combined with recombinant human interferon α 2b can effectively inhibit HPV virus,improve the negative rate of HPV,and also relieve the cervicitis with good safety.更多还原